Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Tax Provisions (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Tax Provisions for 12 consecutive years, with $24000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions rose 105.77% year-over-year to $24000.0, compared with a TTM value of -$1.3 million through Dec 2025, up 23.01%, and an annual FY2025 reading of -$1.8 million, up 8.47% over the prior year.
  • Tax Provisions was $24000.0 for Q4 2025 at Enanta Pharmaceuticals, up from -$80000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $48.5 million in Q3 2021 and bottomed at -$9.4 million in Q2 2021.
  • Average Tax Provisions over 5 years is $1.5 million, with a median of -$363000.0 recorded in 2024.
  • Peak annual rise in Tax Provisions hit 1044.3% in 2023, while the deepest fall reached 11664.71% in 2023.
  • Year by year, Tax Provisions stood at -$36000.0 in 2021, then increased by 5.56% to -$34000.0 in 2022, then plummeted by 1729.41% to -$622000.0 in 2023, then soared by 33.12% to -$416000.0 in 2024, then soared by 105.77% to $24000.0 in 2025.
  • Business Quant data shows Tax Provisions for ENTA at $24000.0 in Q4 2025, -$80000.0 in Q3 2025, and $29000.0 in Q2 2025.